PsoriasisNCT07709169
Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients
An observational study of Psoriasis and Quality of Life, run by Tanta University at 1 site in Egypt.
Trial summary
This work aimed to study some epidemiological features and the clinical profile of patients having psoriasis visiting the Dermatology and Venereology departments of Tanta University Hospitals and to assess the impact of disease on their quality of life. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psoriasis, Quality of Life
- What is being tested?
- Quality of Life assessment
- How many people
- 170 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2023to 1 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study is a cross-sectional study to detect some clinical, epidemiological as well as Quality of Life-related features of psoriasis. All included patients will be collected from the outpatient clinic of The Dermatology \& Venereology Department, Tanta University Hospitals.
Who may be able to join
- Psoriatic patients of both genders aged ≥18 years old.
- Patients accepted to be enrolled in this study.
Who cannot join
- Patients below 18 years old.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Some Epidemiological Features and Clinical Profile of Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients Attending Tanta University Hospitals
This work aimed to study some epidemiological features and the clinical profile of patients having psoriasis visiting the Dermatology and Venereology departments of Tanta University Hospitals and to assess the impact of disease on their quality of life.
Read the detailed description
Psoriasis is a genetically determined, systemic immune-mediated inflammatory disease that affects predominantly the skin and joints. It is now recognized as a systemic disease, which is associated with multiple comorbidities, including diabetes, hypertension, obesity, and major cardiovascular adverse events. These can shorten the lifespan of patients with severe disease by up to 5 years.
The presentation of psoriasis varies from dusky red scaly papules to raised plaques on the elbows, knees, or scalp to superficial pustules dispersed on the palms or soles or, in rare cases, widespread pustules all over the body. The plaque, guttate, small plaque, inverse, erythrodermic, and pustular forms of psoriasis are among the clinical spectrum's variants. Psoriasis can be diagnosed clinically. However, a skin biopsy may be required for cases in which the presentation is not typical.
- Conditions
- Psoriasis, Quality of Life
- Being tested
- Quality of Life assessment
- Medical subject headings
- Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quality of Life assessmentOther
Patients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults.
Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30:
0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Patients with psoriasis. Receives: Other: Quality of Life assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dermatology Life Quality Index (DLQI)
Patients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults.
Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30:
0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life.
Measured: Six months after the survey.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start1 Apr 2023
- Primary completion1 Oct 2024
- Study completion1 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PsoriasisStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 170 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hagar Atteya Al-Sharnoby, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07709169
- Sponsor's protocol ID
- 36264MS82/2/23
- Status last verified
- Jul 2026
- First submitted
- 11 Jul 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Some Epidemiological Features and Clinical Profile of Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients Attending Tanta University Hospitals
- ClinicalTrials.gov ID
- NCT07709169
- Acronym / sponsor ID
- 36264MS82/2/23
- Conditions
- Psoriasis, Quality of Life
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 170 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Apr 2023 (actual)
- Primary completion
- 1 Oct 2024 (actual)
- Study completion
- 1 Oct 2024 (actual)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This work aimed to study some epidemiological features and the clinical profile of patients having psoriasis visiting the Dermatology and Venereology departments of Tanta University Hospitals and to assess the impact of disease on their quality of life.
Detailed description
Psoriasis is a genetically determined, systemic immune-mediated inflammatory disease that affects predominantly the skin and joints. It is now recognized as a systemic disease, which is associated with multiple comorbidities, including diabetes, hypertension, obesity, and major cardiovascular adverse events. These can shorten the lifespan of patients with severe disease by up to 5 years.
The presentation of psoriasis varies from dusky red scaly papules to raised plaques on the elbows, knees, or scalp to superficial pustules dispersed on the palms or soles or, in rare cases, widespread pustules all over the body. The plaque, guttate, small plaque, inverse, erythrodermic, and pustular forms of psoriasis are among the clinical spectrum's variants. Psoriasis can be diagnosed clinically. However, a skin biopsy may be required for cases in which the presentation is not typical.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study group | – | Other: Quality of Life assessmentPatients with psoriasis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study is a cross-sectional study to detect some clinical, epidemiological as well as Quality of Life-related features of psoriasis. All included patients will be collected from the outpatient clinic of The Dermatology \& Venereology Department, Tanta University Hospitals.
Key inclusion criteria (2 listed)
- Psoriatic patients of both genders aged ≥18 years old.
- Patients accepted to be enrolled in this study.
Key exclusion criteria (1 listed)
- Patients below 18 years old.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quality of Life assessmentPatients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults. Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30: 0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life. | Other | Study group |
Primary outcome
Dermatology Life Quality Index (DLQI)
Time frame: Six months after the survey.
Patients completed the Dermatology Life Quality Index (DLQI), which includes 10 questions and is designed for use in adults. Each question is scored on a 4-point scale from 0 ("Not at all") to 3 ("Very much") to assess the past seven days, providing a total score ranging from 0 to 30: 0 - 1: No effect at all on patient's life. 2 - 5: Small effect on patient's life. 6 - 10: Moderate effect on patient's life. 11 - 20: Very large effect on patient's life. 21 - 30: Extremely large effect on patient's life.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Psoriasis
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
Active, not recruitingPhase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriasis and Quality of Life, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dermatology Life Quality Index (DLQI) (time frame: Six months after the survey.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.